 |
|
Anthracyclines improve survival in HER2-positive breast cancer patients
December 26, 2007Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors, according to a study published online December 25 in the Journal of the National Cancer Institute.
Randomized clinical trials have demonstrated that treating early breast cancer with anthracycline-based chemotherapy improves disease-free and overall survival rates more than non-anthracycline-based regimens. However, the studies have demonstrated that anthracyclines may slightly increase the risk of heart damage and leukemia. Given these side effects, the greatest benefit of these regimens may be in women with breast tumors that overexpress HER2-a gene that is often amplified in tumors that respond to anthracyclines.
Alessandra Gennari, M.D., Ph.D., of the National Cancer Research Institute in Genoa, Italy, and colleagues compiled data from eight randomized controlled trials that compared anthracyclines and non-anthracyclines, and also reported HER2 status. Almost 30 percent of the patients' tumors overexpressed HER2.
Overall and among patients with HER2-positive tumors, anthracycline-based chemotherapy produced a greater reduction in the risk of relapse or death than non-anthracycline-based regimens. However, among patients with HER2-negative tumors, there was no difference in survival between the chemotherapy regimens.
"The absence-of any effect of anthracyclines observed in patients with HER2-negative disease suggests that this group of patients could be spared unnecessary toxic effects related to the use of this class of agents and raises questions as to the appropriateness of control arms in randomized clinical trials in which anthracycline-based regimens are used in unselected patient populations," the authors write.
In an accompanying editorial, Soonmyung Paik, M.D., of the National Surgical Adjuvant Breast and Bowel Project in Pittsburgh and colleagues point out that HER2 status alone may not be enough to determine who should receive anthracyclines, given the molecular differences among different subtypes of breast cancer.
"Optimization of adjuvant chemotherapy for patients diagnosed with breast cancer will depend on defining the baseline prognosis and chemosensitivity of each subclass of breast cancer beyond those crudely defined by HER2 status alone," the editorialists write.
Journal of the National Cancer Institute
Overall and among patients with HER2-positive tumors, anthracycline-based chemotherapy produced a greater reduction in the risk of relapse or death than non-anthracycline-based regimens. However, among patients with HER2-negative tumors, there was no difference in survival between the chemotherapy regimens.
"The absence-of any effect of anthracyclines observed in patients with HER2-negative disease suggests that this group of patients could be spared unnecessary toxic effects related to the use of this class of agents and raises questions as to the appropriateness of control arms in randomized clinical trials in which anthracycline-based regimens are used in unselected patient populations," the authors write.
In an accompanying editorial, Soonmyung Paik, M.D., of the National Surgical Adjuvant Breast and Bowel Project in Pittsburgh and colleagues point out that HER2 status alone may not be enough to determine who should receive anthracyclines, given the molecular differences among different subtypes of breast cancer.
"Optimization of adjuvant chemotherapy for patients diagnosed with breast cancer will depend on defining the baseline prognosis and chemosensitivity of each subclass of breast cancer beyond those crudely defined by HER2 status alone," the editorialists write.
Journal of the National Cancer Institute
Anthracyclines News and Current Anthracyclines Events RSSHerceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centre trial to investigate this treatment.
Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
The first study to investigate the effects of chemotherapy on metastatic breast cancer in women with the BRCA1 or BRCA2 gene mutation has shown that standard chemotherapy works better in these patients than in women without the BRCA1/2 mutation.
Childhood cancer survivors at increased risk of sarcoma
Survivors of childhood cancers have a ninefold increased risk of developing a secondary sarcoma—a cancer of connective or supportive tissue such as bone, fat, or muscle—compared with the general population.
Study analyzes heart attack mortality risk associated with Hodgkin disease treatments
Doctors have long known that patients treated for Hodgkin disease are at an increased risk for heart attacks.
Genes raise risk of heart disease after treatment for childhood cancer
Gene variations may raise the risk that survivors of childhood cancer will suffer congestive heart failure as a complication of drugs they received during cancer treatment.
Innovative research set to push boundaries of cancer care
Cancer researchers wielding opportunistic bacteria, vaccines, electric pulses, nano buckeyballs, and designer agents that enter the brain are being featured in a "Novel Approaches" press conference at the Molecular Targets and Cancer Therapeutics International Conference.
More children survive cancer but the after-effects present a challenge to doctors
Embargoed: 09.00 hrs CET Wednesday 24 September 2003 Copenhagen, Denmark: The number of children who survive childhood cancer is improving dramatically, but because of the side effects of their treatment the majority continue to need specialist care for many years. This rapid increase in the numbers of survivors means that the medical profession must consider the best and most cost-effective way of caring for them, according to Jill Mann, Professor of Paediatric Oncology at the University of Birmingham, and Emeritus Consultant Paediatric Oncologist at the Birmingham Children's Hospital in the UK. Prof. Mann told delegates at ECCO12 - The European Cancer Conference that a study of 5,016 child
Avoiding heart failure after cancer drugs - new hope for early diagnosis, treatment and prevention of cardiotoxicity
New hope that heart failure - a potentially fatal side effect of some types of cancer drugs - can be diagnosed early and successfully treated or even prevented, is reported today (Thursday 2 May) in Annals of Oncology, journal of the European Society for Medical Oncology. A team from the University of Milan* has found evidence that elevated blood plasma levels of a cardiac peptide called troponin I may be an early warning that a patient will develop heart failure even though the heart appears to be functioning normally. In a second study, doctors from the University of Copenhagen** report that ACE inhibitors restored cardiac function in breast cancer patients who had developed congestive hea
More Anthracyclines News Articles
| © 2008 BrightSurf.com |